European Committee for Treatment and Research in Mulitple Sclerosis 2018
The 34th Congress of the European Committee for Treatment and Research in Mulitple Sclerosis (ECTRIMS) was held in Berlin, Germany, from October 10 to 12, 2018. The congress covered all the latest and exciting new developments in multiple sclerosis, including treatment, genetics, pathology, imaging, immunology, and epidemiology.
The principal medical science director at Genentech spoke about the decisions behind the tools being used for measurement, and what the neurologists can get from the data.
The medical director of the UCSF Multiple Sclerosis Center discussed the idea behind remyelination and shared his thoughts on what the best shot at developing a therapy might be.
For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.
The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.
The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.
The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.
.png)
.png)
.png)
.png)
.png)
.png)
